Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Cocktail & Poster Display session

71P - Molecular Tumor Board at the European Institute of Oncology: An early Italian precision oncology experience


06 Mar 2023


Cocktail & Poster Display session


Edoardo Crimini


Annals of Oncology (2023) 8 (1suppl_2): 100897-100897. 10.1016/esmoop/esmoop100897


E. Crimini1, M. Repetto1, L. Boscolo Bielo1, E. Guerini-Rocco2, L. Ascione1, C. Zanzottera3, L. Mazzarella1, A. Ranghiero2, C. Belli1, C. Criscitiello4, A. Esposito5, M. Barberis2, G. Curigliano1

Author affiliations

  • 1 Early Drug Development for Innovative Therapies Division, IEO - Istituto Europeo di Oncologia, 20141 - Milan/IT
  • 2 Division Of Pathology, IEO - Istituto Europeo di Oncologia, 20141 - Milan/IT
  • 3 Division Of Cancer Prevention And Genetics, IEO - Istituto Europeo di Oncologia IRCCS, 20141 - Milan/IT
  • 4 Division Of Experimental Therapeutics, IEO - Istituto Europeo di Oncologia IRCCS, 20141 - Milan/IT
  • 5 Early Drug Development For Innovative Therapies Division, Istituto Europeo di Oncologia, 20141 - Milan/IT


This content is available to ESMO members and event participants.

Abstract 71P


Precision oncology personalizes treatments for cancer patients, aiming to improve their clinical outcomes. ESMO Scale for Clinical Actionability of Molecular Targets (ESCAT) allows evidence-based evaluation of genomic findings. Molecular tumor boards (MTBs) multi-disciplinary expertise enables ESCAT implementation and personalized treatment choice.


We retrospectively reviewed outcomes of patients discussed at European Institute of Oncology MTB between June 2019 and June 2022. We performed descriptive statistics and survival analysis comparing patients that received molecularly-matched treatments (MMT) and non-matched treatments (nMMT).


MTB discussed 251 patients with cancer encompassing 26 different primary cancer types. Breast cancer accounted for 25.5% of the total. 188 (74.6%) patients had at least one actionable alteration. After MTB discussion, 76 patients received MMT while 76 received nMMT. Patients receiving MMT displayed higher overall response rate (37.3% vs 12.9%), median progression-free-survival (PFS 5.8 months, 95% CI 4.1–7.5 vs 3.6 months, 95% CI 2.5–4.8, p=0.041; HR 0.679, 95% CI 0.467–0.987) and median overall-survival (mOS 35.1 months, 95% CI not evaluable vs 8.5 months, 95% CI 3.8 – 13.2; HR 0.431, 95% CI 0.250 – 0.744, p=0.002). Superiority in OS and PFS persisted in multivariable models. Among 61 pretreated patients receiving MMT, 37.5% had superior PFS compared to the prior line (PFS2/PFS1 ratio ≥ 1.3). Higher OS (p=0.001) and PFS (p=0.049) were observed for patients with higher actionability evidence (ESCAT tier I) alterations, while no difference was observed in lower evidence levels. Table: 71P
Most frequent actionable genes

Alteration Total number Treated patients Drug administered ESCAT at discussion ORR
PIK3CA 51 4 Alpelisib IA 1/4 (25%)
BRCA2 32 19 PARP-i IA 7/19 (37%)
BRAF V600 20 2 BRAF + MEK-i IIIA 1/2 (50%)
ERBB2 17 1 Trastuzumab + pertuzumab IIIA 1/1 (100%)
TMB-HIGH 16 4 Anti-PD(L)-1 IC 2/4 (50%)
ATM 15 2 PARP-i X 0/2 (0%)
MSI-HIGH 14 8 Anti-PD(L)-1 IC 4/8 (50%)
BRCA1 11 9 PARP-i IA 2/9 (22%)
RET 10 10 RET-i IIIA 7/10 (70%)


We report real-world data of the first Italian experience of MTB application in clinical practice. Our work shows that MTBs can yield valuable clinical benefit in terms of OS and PFS. Biomarkers with lower actionability ESCAT level appear to be linked to lower clinical benefit.

Clinical trial identification

This study is approved by IEO Ethical Committee with the reference number UID 3572.

Editorial acknowledgement


Legal entity responsible for the study

E. Crimini, M. Repetto.


Has not received any funding.


E. Guerini-Rocco: Financial Interests, Personal, Advisory Role: AstraZeneca, GSK, Roche, Termo Fisher; Financial Interests, Personal, Advisory Board: Novartis. C. Criscitiello: Financial Interests, Personal, Invited Speaker: Pfizer, Novartis, Eli Lilly, Roche, Gilead; Financial Interests, Personal, Advisory Board: MSD, Seagen, AstraZeneca, Daiichi Sankyo. A. Esposito: Financial Interests, Personal, Speaker’s Bureau: Novartis. G. Curigliano: Financial Interests, Personal, Invited Speaker: Roche, AstraZeneca, Daiichi Sankyo, Novartis, Pfizer; Financial Interests, Personal, Advisory Board: Ellipsis, Roche, AstraZeneca, Daiichi Sankyo, Lilly, Pfizer, Veracyte, BMS, Merck, Exact Sciences, Celcuity; Financial Interests, Institutional, Research Grant, Investigator Initiated Trial: Merck; Financial Interests, Institutional, Funding, Phase I studies: BMS, Novartis, AstraZeneca, Daiichi Sankyo, Roche, Blueprint Medicine, Kymab, Astellas, Sanofi, Philogen; Financial Interests, Institutional, Invited Speaker, Phase I clinical basket trial: Relay Therapeutics; Non-Financial Interests, Personal, Officer, Italian National Health Council as Advisor for Ministry of Health: Consiglio Superiore di Sanità; Non-Financial Interests, Personal, Advisory Role, Member of the Scientific Council. Patient Advocacy Association: Europa Donna; Non-Financial Interests, Personal, Advisory Role, Cancer Research Foundation: Fondazione Beretta; Non-Financial Interests, Personal, Invited Speaker, No compensation for this role. This a public national company for cancer prevention: Lega Italiana Lotta ai Tumori; Non-Financial Interests, Personal, Officer, Member of the Advisory Council: EUSOMA. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.